ArticleThe Journal of general virology2004
Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver.
Article in The Journal of general virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 65 citations in OpenAlex.
- Characterization of a multipurpose NS3 surface patch coordinating HCV replicase assembly and virion morphogenesis.PLoS pathogens · 2022Article
- Review
- Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies.Sensors (Basel, Switzerland) · 2019Review
- The acidic domain of the hepatitis C virus NS4A protein is required for viral assembly and envelopment through interactions with the viral E1 glycoprotein.PLoS pathogens · 2019Article
- Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries.The Indian journal of medical research · 2018Review
- Regulation of hepatitis C virus replication via threonine phosphorylation of the NS5A protein.The Journal of general virology · 2018Article
- Newly discovered hepatitis C virus minicores circulate in human blood.Hepatology communications · 2018Article
- Article
- The role of HCV proteins on treatment outcomes.Virology journal · 2015Review
- HCV Envelope protein 2 sequence comparison of Pakistani isolate and In-silico prediction of conserved epitopes for vaccine development.Journal of translational medicine · 2013Article
- Hepatitis C virus: virology and life cycle.Clinical and molecular hepatology · 2013Review
- HCV entry receptors as potential targets for siRNA-based inhibition of HCV.Genetic vaccines and therapy · 2011Article
- Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2.Virology journal · 2011Article
- Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence.Virology journal · 2011Review
- Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV.Virology journal · 2011Article
- Hepatitis C virus e2 protein ectodomain is essential for assembly of infectious virions.International journal of hepatology · 2011Article
- Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins.PloS one · 2009Article
- Primary hepatocytes as targets for hepatitis C virus replication.Journal of viral hepatitis · 2008Review
- Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.Journal of virology · 2008Article
- Characterization of hepatitis C RNA-containing particles from human liver by density and size.The Journal of general virology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
In the absence of satisfactory cell culture systems for hepatitis C virus (HCV), virtually all that is known about the proteins of the virus has been learned by the study of recombinant proteins. Characterization of virus proteins from patients with HCV has been retarded by the low virus titre in blood and limited availability of infected tissue. Here, the authors have identified a primary infection in a liver transplanted into an immunodeficient patient with chronic HCV. The patient required re-transplant and the infected liver, removed 6 weeks after the initial transplant, had a very high titre of HCV, 5 x 10(9) International Units (IU) per gram of liver. The density distribution of HCV in iodixanol gradients showed a peak at 1.04 g x ml(-1) with 73 % of virus below 1.08 g x ml(-1). Full-length HCV RNA was detected by Northern blotting and the ratio between positive- and negative-strand HCV RNA was determined as 60. HCV was partially purified by precipitation with heparin/Mn(2+) and a single species of each of the three structural proteins, core, E1 and E2, was detected by Western blotting. The molecular mass of core was 20 kDa, which corresponds to the mature form from recombinant sources. The molecular mass of glycoprotein E1 was 31 kDa before and 21 kDa after deglycosylation with PNGase F or endoglycosidase H. Glycoprotein E2 was 62 kDa before and 36 kDa after deglycosylation, but E2-P7 was not detected. This was in contrast to recombinant sources of E2 which contain E2-P7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.